<DOC>
	<DOCNO>NCT01607853</DOCNO>
	<brief_summary>The purpose study evaluate anti-psoriatic effect Daivobet® gel apply remove 10 minute ( +/- 2 minute ) , Daivobet® gel apply remove 20 minute ( +/- 2 minute ) compare Daivobet® gel Daivobet® gel vehicle apply 24 hour ( +/- 2 hour ) , use psoriasis plaque test modify method develop KJ Dumas JR Scholtz .</brief_summary>
	<brief_title>A Short-contact Plaque Test Study With Daivobet® Gel Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>1 . Following verbal write information trial , subject provide sign date informed consent study related activity carry . 2 . Age 18 year . 3 . Either sex . 4 . All skin type . 5 . Subjects diagnosis psoriasis vulgaris lesion locate arm , leg and/or trunk . The lesion must total size suitable application 4 different product . 6 . Subjects , opinion investigator , stable psoriasis base Total Plaque Score evaluate screen visit visit 2 ( baseline ) . 7 . Subjects psoriasis lesion ( plaque ) assess Total Clinical Score ( sum score erythema , scale infiltration ) 4 9 inclusive , individual item ≥ 1 . 8 . Subjects willing able follow study procedure complete whole study . 9 . Subjects affiliate social security system . 10 . Female subject childbearing potential use reliable method contraception least 1 month study start course study ( e.g. , oral contraceptive pill , intrauterine device , contraceptive patch , implantable contraception , condom ) female nonchildbearing potential ( i.e . postmenopausal ( absence menstrual bleeding 2 year ) , hysterectomy , bilateral ovariectomy tubal section/ligation ) . 11 . Female negative urine pregnancy test ( screen visit ) . 1 . Females pregnant , childbearing potential wish become pregnant study , breast feeding . 2 . Systemic treatment biological therapy ( market market ) possible effect psoriasis vulgaris within 4 week ( etanercept ) , 2 month ( adalimumab , alefacept , infliximab ) , 4 month ( ustekinumab ) 4 weeks/5 halflives ( whichever longer ) experimental biological product prior randomisation study . 3 . Systemic treatment therapy biologicals , potential effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , immunosuppressant ) within 4 week period prior randomisation study . 4 . Use phototherapy within follow time period prior randomisation study : PUVA Grenz ray therapy ( 4 week ) , UVB ( 2 week ) . 5 . Subjects use one follow topical drug within 4 week prior randomisation study : Potent potent ( WHO group IIIIV ) corticosteroid . 6 . Subjects use one follow topical drug treatment psoriasis within 2 week prior randomisation study : WHO group III corticosteroid ( except use treatment scalp and/or facial psoriasis ) , Topical retinoids , Vitamin D analogue , Topical immunomodulators ( e.g . calcineurin inhibitor ) , Anthracen derivative , Tar , Salicylic acid . 7 . Subjects use emollient target plaque within one week randomisation study . 8 . Initiation , expect change concomitant medication may affect psoriasis vulgaris ( e.g. , beta blocker , antimalaria drug , lithium ACE inhibitor ) within 2 week prior randomisation study . 9 . Subjects current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis . 10 . Subjects known/suspected disorder calcium metabolism associate hypercalcemia within last 10 year , base medical history . 11 . Subjects follow condition present test area : viral ( e.g . herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection atrophic skin . 12 . Subjects skin manifestation relation syphilis tuberculosis , rosacea , perioral dermatitis , acne vulgaris , atrophic skin , stria atrophicae , fragility skin vein , icthyosis , acne rosacea , ulcer wound within plaque test area . 13 . History severe disease serious current condition ( base subject interview and/or result screen physical examination ) , opinion investigator , would put subject risk participating study would interfere significantly evaluation study result study course ( e.g . cancer , severe cardiopathy , severe renal insufficiency , severe hepatic insufficiency ) . 14 . Subjects receive treatment nonmarketed drug substance ( i.e. , agent yet make available clinical use follow registration ) within 4 week period prior randomisation longer , class substance require long washout define ( e.g. , biological treatment ) . 15 . Subjects current participation interventional clinical trial , base interview subject . 16 . Subjects know suspected hypersensitivity component ( ) investigational product . 17 . Subjects concomitant medical dermatological disorder ( ) might preclude accurate evaluation psoriasis . 18 . Subjects foresee intensive solar exposure study ( UV radiation , etc . ) expose within two week precede screen visit . 19 . Subjects impossible contact case emergency . 20 . Subjects know , opinion investigator , unlikely comply Clinical Study Protocol ( e.g . alcoholism , drug dependency psychotic state ) . 21 . Subjects exclusion period National Biomedical Research Register French Ministry Health randomisation . 22 . Subjects guardianship , hospitalize public private institution , reason research subject deprive freedom . 23 . Subjects previously randomise trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>